# A Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Primary Sjögren's Syndrome

> **NCT04078386** · PHASE2 · COMPLETED · sponsor: **RemeGen Co., Ltd.** · enrollment: 42 (actual)

## Conditions studied

- Primary Sjögren's Syndrome

## Interventions

- **BIOLOGICAL:** Placebo
- **BIOLOGICAL:** RC18 240 mg
- **BIOLOGICAL:** RC18 160 mg

## Key facts

- **NCT ID:** NCT04078386
- **Lead sponsor:** RemeGen Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-11-21
- **Primary completion:** 2021-06-23
- **Final completion:** 2021-10-26
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2022-01-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04078386

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04078386, "A Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Primary Sjögren's Syndrome". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04078386. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*